Development of a tissue-engineered composite implant for treating traumatic paraplegia in rats Abstract This study was designed to assess a new composite	1
Development	1
a tissue-engineered composite	16
traumatic paraplegia	67
rats Abstract This study was designed to assess a new composite	91
rats	91
Abstract This study	97
a new composite	140
regeneration of injured spinal cord	174
regeneration	174
injured spinal cord	190
paraplegic rats following complete cord transection	213
paraplegic rats	213
complete cord transection	239
Neuronal xenogeneic cells from biopsies of adult nasal olfactory mucosa -LRB- NOM -RRB- of human origin , or spinal cords of human embryos ,	266
Neuronal xenogeneic cells from biopsies of adult nasal olfactory mucosa -LRB- NOM -RRB- of human origin	266
Neuronal xenogeneic cells	266
biopsies of adult nasal olfactory mucosa -LRB- NOM -RRB- of human origin	297
biopsies	297
adult nasal olfactory mucosa -LRB- NOM -RRB- of human origin	309
adult nasal olfactory mucosa -LRB- NOM -RRB-	309
adult nasal olfactory mucosa	309
NOM	339
human origin	347
spinal cords of human embryos	364
spinal cords	364
human embryos	380
two consecutive stages : stationary cultures in a viscous semisolid gel -LRB- NVR-N-Gel -RRB-	412
two consecutive stages	412
stationary cultures in a viscous semisolid gel -LRB- NVR-N-Gel -RRB-	436
stationary cultures	436
a viscous semisolid gel -LRB- NVR-N-Gel -RRB-	459
a viscous semisolid gel	459
NVR-N-Gel	484
suspension on positively charged microcarriers -LRB- MCs -RRB-	502
suspension	502
positively charged microcarriers -LRB- MCs -RRB-	516
positively charged microcarriers	516
MCs	550
A tissueengineered tubular scaffold , containing bundles of parallel nanofibers ,	556
A tissueengineered tubular scaffold	556
bundles of parallel nanofibers	604
bundles	604
parallel nanofibers	615
Both the tube and the nanofibers	651
the tube	656
the nanofibers	669
a biodegradable dextran sulphate -- gelatin co-precipitate	697
a biodegradable dextran sulphate	697
gelatin co-precipitate	730
The suturable scaffold	754
the	786
the site of injury	801
the site	801
injury	813
the regenerating axons	846
Implants of adult human NOM cells	870
Implants	870
adult human NOM cells	882
eight rats , from which a 4 mm segment of the spinal cord had been completely removed	924
eight rats	924
a 4 mm segment of the spinal cord	947
a 4 mm segment	947
the spinal cord	965
Another four rats whose spinal cords had also been transected	1010
Another four rats	1010
spinal cords	1034
a composite	1092
human embryonic spinal cord cells	1124
Eight other cord-transected rats	1159
a control group	1202
Physiological and behavioral analysis , performed 3 months after implantation ,	1219
Physiological and behavioral analysis	1219
3 months	1268
implantation	1283
partial recovery of function in one or two limbs in three out of eight animals of the NOM implanted group and in all the four rats that were implanted with cultured human embryonic spinal cord cells	1306
partial recovery	1306
function in one or two limbs in three out of eight animals of the NOM implanted group and in all the four rats that were implanted with cultured human embryonic spinal cord cells	1326
function in one	1326
function	1326
one	1338
two limbs in three out of eight animals of the NOM implanted group and in all the four rats that were implanted with cultured human embryonic spinal cord cells	1345
two limbs	1345
three	1358
eight animals of the NOM implanted group	1371
eight animals	1371
the NOM implanted group	1388
all the four rats that were implanted with cultured human embryonic spinal cord cells	1419
all the four rats	1419
human embryonic spinal cord cells	1471
Animals of the control group	1506
Animals	1506
the control group	1517
transmission of stimuli	1582
transmission	1582
stimuli	1598
the brain	1609
The utilization of an innovative composite	1620
The utilization	1620
an innovative composite	1639
a gap resulting from the transection and removal of a 4 mm	1681
a gap	1681
the transection and removal of a 4 mm	1702
the transection and removal	1702
a 4 mm	1733
spinal cord segment	1740
promise	1766
the feasibility of this approach for partial reconstruction of spinal cord lesions	1786
the feasibility	1786
this approach for partial reconstruction of spinal cord lesions	1805
this approach	1805
partial reconstruction of spinal cord lesions	1823
partial reconstruction	1823
spinal cord lesions	1849
Such an	1870
a vital bridging station in acute and chronic cases of paraplegia	1899
a vital bridging station	1899
acute and chronic cases	1927
paraplegia	1954
Introduction Spinal cord injuries involving partial or complete transection	1967
Introduction Spinal cord injuries	1967
Introduction	1967
Spinal cord injuries	1980
partial or complete transection	2011
other lesions in the central nervous system	2052
other lesions	2052
the central nervous system	2069
their own	2119
Complete spinal cord injuries in humans and other mammals	2130
Complete spinal cord injuries	2130
humans and other mammals	2163
humans	2163
other mammals	2174
loss of sensory , motor and , reflex functions below the site of injury	2194
loss of sensory	2194
loss	2194
sensory	2202
motor	2211
reflex functions below the site of injury	2222
reflex functions	2222
the site of injury	2245
the site	2245
injury	2257
Several different approaches	2265
an injured spinal cord	2338
The use of growth factors , either by exogenous administration -LSB- 8 , 14 , 36 -RSB- or by introducing growth factor-treated implants -LSB- 22 , 23 , 39 -RSB- and genetically engineered cells -LSB- 34 , 46 -RSB-	2362
The use	2362
growth factors	2373
by exogenous administration -LSB- 8 , 14 , 36 -RSB- or by introducing growth factor-treated implants -LSB- 22 , 23 , 39 -RSB- and genetically engineered cells -LSB- 34 , 46	2396
by exogenous administration -LSB- 8 , 14 , 36 -RSB- or by introducing growth factor-treated implants -LSB- 22 , 23 , 39 -RSB- and genetically engineered cells	2396
by exogenous administration -LSB- 8 , 14 , 36 -RSB- or by introducing growth factor-treated implants -LSB- 22 , 23 , 39 -RSB-	2396
exogenous administration	2399
-LSB- 8 , 14 , 36	2424
growth factor-treated implants	2454
-LSB- 22 , 23 , 39 -RSB-	2485
genetically engineered cells	2502
-LSB- 34 , 46	2531
limited success	2565
Others	2582
their efforts on the use of various tissue-engineered scaffolds	2607
their efforts	2607
the use of various tissue-engineered scaffolds	2624
the use	2624
various tissue-engineered scaffolds	2635
-LSB- 4 , 54 , 57 -RSB-	2671
Spinal cord reconstruction using implantation of cells from various sources	2684
Spinal cord reconstruction	2684
implantation of cells from various sources	2717
implantation	2717
cells from various sources	2733
cells	2733
various sources	2744
momentum	2777
recent years	2789
-LSB- 28 , 41 -RSB-	2802
one of the major disadvantages of the implantation or injection of cells	2821
one	2821
the major disadvantages of the implantation or injection of cells	2828
the major disadvantages	2828
the implantation or injection of cells	2855
the implantation or injection	2855
cells	2888
the limited viable cell survival after the procedure	2903
the limited viable cell survival	2903
the procedure	2942
cells	2960
the injury site	2981
One feasible innovative way of repairing injured mammalian spinal cord	2998
One feasible innovative way	2998
injured mammalian spinal cord	3039
a composite	3084
cells	3129
an autologous or allogeneic source	3140
The implanted cells	3176
a vital bridge to connect the stumps of the severed spinal cords -LSB- 44 -RSB-	3214
the stumps of the severed spinal cords -LSB- 44 -RSB-	3240
the stumps	3240
the severed spinal cords -LSB- 44 -RSB-	3254
the severed spinal cords	3254
44 -RSB-	3280
Such a composite spinal cord	3285
a combination of the various elements that support the healing process , such as a tissue-engineered scaffold to anchor the implanted cells , which are embedded in a viscous adhesive milieu , supplemented with a variety of factors -LSB- 47 -RSB-	3331
a combination	3331
the various elements that support the healing process , such as a tissue-engineered scaffold to anchor the implanted cells , which are embedded in a viscous adhesive milieu , supplemented with a variety of factors -LSB- 47 -RSB-	3348
the various elements	3348
the healing process , such as a tissue-engineered scaffold to anchor the implanted cells , which are embedded in a viscous adhesive milieu ,	3382
the healing process	3382
a tissue-engineered scaffold to anchor the implanted cells	3411
the implanted cells	3450
a viscous adhesive milieu	3493
a variety of factors -LSB- 47 -RSB-	3538
a variety	3538
factors -LSB- 47 -RSB-	3551
factors	3551
47 -RSB-	3560
The dream of using primordial cells from early human embryos for implantation therapy in spinal cord injuries	3565
The dream	3565
primordial cells	3584
early human embryos for implantation therapy in spinal cord injuries	3606
early human embryos	3606
implantation therapy in spinal cord injuries	3630
implantation therapy	3630
spinal cord injuries	3654
a step	3682
reality	3699
-LSB- 27 , 37 -RSB-	3707
Recent discoveries	3717
the potential for isolation and cultivation of human embryonic stem cells -LSB- 49 -RSB- , and their differentiation in culture to neurons and other cell types -LSB- 43 , 49 -RSB-	3743
the potential	3743
isolation and cultivation	3761
human embryonic stem cells -LSB- 49 -RSB- , and their differentiation in culture to neurons and other cell types -LSB- 43 , 49 -RSB-	3790
human embryonic stem cells	3790
49 -RSB- , and their differentiation in culture to neurons and other cell types -LSB- 43 , 49 -RSB-	3818
49 -RSB-	3818
their differentiation in culture to neurons and other cell types -LSB- 43 , 49	3827
their differentiation	3827
culture to neurons and other cell types -LSB- 43 , 49	3852
culture	3852
neurons and other cell types	3863
neurons	3863
other cell types	3875
-LSB- 43 , 49	3892
viable treatment of spinal cord injuries using such human embryonic stem cells	3915
viable treatment	3915
spinal cord injuries using such human embryonic stem cells	3935
spinal cord injuries	3935
such human embryonic stem cells	3962
an allogeneic graft	4017
the risks of rejection , immunogenic reaction and possible neoplastic transformation	4058
the risks	4058
rejection , immunogenic reaction and possible neoplastic transformation	4071
rejection	4071
immunogenic reaction	4082
possible neoplastic transformation	4107
An excellent autologous source of adult neuronal precursor cells	4143
An excellent autologous source	4143
adult neuronal precursor cells	4177
the nasal olfactory mucosa -LRB- NOM -RRB-	4211
the nasal olfactory mucosa	4211
NOM	4239
The NOM tissue	4245
the neurons and the sustentacular cells of the NOM	4283
the neurons	4283
the sustentacular cells of the NOM	4299
the sustentacular cells	4299
the NOM	4326
themselves	4340
life by proliferation of the basal global stem cells -LSB- 9 , 15	4369
life	4369
proliferation of the basal global stem cells -LSB- 9 , 15	4377
proliferation	4377
the basal global stem cells	4394
-LSB- 9 , 15	4422
45	4430
the unique sensory characteristics of the NOM neurons	4445
the unique sensory characteristics	4445
the NOM neurons	4483
them	4506
signals as a	4551
signals	4551
a	4562
relay station '' in the spinal cord	4566
relay station	4566
the spinal cord	4585
The scaffolds produced by tissue-engineering technologies for spinal cord implantation	4602
The scaffolds	4602
tissue-engineering technologies for spinal cord implantation	4628
tissue-engineering technologies	4628
spinal cord implantation	4664
synthetic and naturally occurring polymeric macromolecules	4710
synthetic	4710
naturally occurring polymeric macromolecules	4724
The naturally occurring ones	4770
protein-peptides-based scaffolds and carbohydrates	4825
scaffolds	4883
-LSB- 26 , 29 , 52 -RSB-	4893
There	4907
several published examples where the scaffold imitates the extracellular matrix -LRB- ECM -RRB- present in connective tissues , such as collagens and proteoglycans -LSB- 55 , 59 , 60 -RSB-	4917
several published examples	4917
the scaffold	4950
the extracellular matrix -LRB- ECM -RRB- present in connective tissues , such as collagens and proteoglycans	4972
the extracellular matrix -LRB- ECM -RRB- present in connective tissues	4972
the extracellular matrix -LRB- ECM -RRB-	4972
the extracellular matrix	4972
ECM	4998
connective tissues	5014
collagens and proteoglycans	5042
-LSB- 55 , 59 , 60 -RSB-	5070
The latter type best	5084
The latter type	5084
best	5100
the ECM constituents of many tissues , including that of the spinal cord	5113
the ECM constituents	5113
many tissues	5137
that of the spinal cord	5161
that	5161
the spinal cord	5169
Other promising strategies	5186
a receptive environment for regeneration	5231
a receptive environment	5231
regeneration	5259
the myelin-associated inhibitors of axonal growth and the physical and biochemical barrier , the so-called `` glial scar ''	5286
the myelin-associated inhibitors of axonal growth	5286
the myelin-associated inhibitors	5286
axonal growth	5322
the physical and biochemical barrier , the so-called `` glial scar ''	5340
the physical and biochemical barrier	5340
the so-called `` glial scar ''	5378
-LSB- 7 , 17 , 40 , 48 , 53 -RSB-	5407
Last , but not the least important ,	5428
Last	5428
not the least important	5438
not the	5438
the intercellular viscous adhesive milieu and its ingredients for supporting the vitality of the neuronal bridge	5466
the intercellular viscous adhesive milieu	5466
its ingredients for supporting the vitality of the neuronal bridge	5512
its ingredients	5512
the vitality of the neuronal bridge	5543
the vitality	5543
the neuronal bridge	5559
The ECM ground substances of the spinal cord	5580
The ECM ground substances	5580
the spinal cord	5609
the consistency of colloidal-gels	5630
the consistency	5630
colloidal-gels	5649
several types of gels	5677
several types	5677
gels	5694
injured spinal cord	5732
-LSB- 34 , 56 , 57 -RSB-	5752
the current study	5769
we	5787
the development of an innovative composite implant designed to serve as a vital bridging station in acute and chronic cases of spinal transection or injury	5800
the development	5800
an innovative composite implant designed to serve as a vital bridging station in acute and chronic cases of spinal transection or injury	5819
an innovative composite	5819
a vital bridging station in acute and chronic cases of spinal transection or injury	5872
a vital bridging station	5872
acute and chronic cases	5900
spinal transection or injury	5927
Materials and methods The composite	5958
Materials	5958
methods The composite	5972
methods	5972
The composite	5980
elements The scaffold is based on NVRs tissue-engineered technology -LRB- patent pending -RRB- , consisting of two naturally occurring biological cross-linked polymers	6002
elements	6002
The scaffold	6011
NVRs tissue-engineered technology -LRB- patent pending -RRB- , consisting of two naturally occurring biological cross-linked polymers	6036
NVRs tissue-engineered technology -LRB- patent pending -RRB- , consisting of two	6036
NVRs tissue-engineered technology	6036
NVRs	6036
tissue-engineered technology	6041
patent pending	6071
patent	6071
two	6102
biological cross-linked polymers	6126
It	6160
a tubular format with a customized diameter of 2 mm and a wall thickness of 0.4 mm	6167
a tubular format	6167
a customized diameter of 2 mm and a wall thickness of 0.4 mm	6189
a customized diameter of 2 mm	6189
a customized diameter	6189
2 mm	6214
a wall thickness of 0.4 mm	6223
a wall thickness	6223
0.4 mm	6243
addition	6254
the tubular scaffold	6264
a bundle of parallel nanofibers 50 -- 100 µm in diameter , made of the same material as the scaffold -LRB- Fig. 1 -RRB-	6294
a bundle	6294
parallel nanofibers 50 -- 100 µm in diameter , made of the same material as the scaffold -LRB- Fig. 1 -RRB-	6306
parallel nanofibers 50 -- 100 µm in diameter	6306
parallel nanofibers 50	6306
parallel nanofibers	6306
50	6326
100 µm in diameter	6330
100 µm	6330
diameter	6340
the same material as the scaffold -LRB- Fig. 1 -RRB-	6358
the same material	6358
the scaffold -LRB- Fig. 1 -RRB-	6379
the scaffold	6379
Fig. 1	6393
a series of preliminary experiments	6405
a series	6405
preliminary experiments	6417
the scaffold	6441
data not shown	6518
data	6518
The tube	6535
it	6575
a period of more than 3 months	6591
a period	6591
more than 3 months	6603
biodegradation	6628
place -LRB- data not shown -RRB-	6649
place	6649
data not shown	6656
data	6656
NVR-N-Gel , which is a proprietary product of NVR Labs -LRB- patent pending -RRB- ,	6673
NVR-N-Gel	6673
a proprietary product of NVR Labs -LRB- patent pending -RRB-	6693
a proprietary product	6693
NVR Labs -LRB- patent pending -RRB-	6718
NVR Labs	6718
patent pending	6728
patent	6728
a crosslinked hyaluronic acid with the adhesive molecule laminin , and the following mixture of ingredients : antioxidants , neuronal growth factor ; neuro-protective factors ; EGF , bFGF , BDNF and NGF -- 20 -- 50 ng/ml , IGF-I -- 50 ng/ml , LIF -- 0.5 u/ml , NAC -LRB- n-acetyl cystein -RRB- -- 10 µM , pifithrin a , cyclic -- 200 nM , and retinoic acid -- 1 -- 5 µM	6760
a crosslinked hyaluronic acid with the adhesive molecule laminin	6760
a	6760
hyaluronic acid	6774
the adhesive molecule laminin	6795
the following mixture of ingredients : antioxidants , neuronal growth factor ; neuro-protective factors ; EGF , bFGF , BDNF and NGF -- 20 -- 50 ng/ml , IGF-I -- 50 ng/ml , LIF -- 0.5 u/ml , NAC -LRB- n-acetyl cystein -RRB- -- 10 µM , pifithrin a , cyclic -- 200 nM , and retinoic acid -- 1 -- 5 µM	6830
the following mixture	6830
ingredients : antioxidants , neuronal growth factor ; neuro-protective factors ; EGF , bFGF , BDNF and NGF -- 20 -- 50 ng/ml , IGF-I -- 50 ng/ml , LIF -- 0.5 u/ml , NAC -LRB- n-acetyl cystein -RRB- -- 10 µM , pifithrin a , cyclic -- 200 nM , and retinoic acid -- 1 -- 5 µM	6855
ingredients	6855
antioxidants , neuronal growth factor	6868
antioxidants	6868
neuronal growth factor	6882
neuro-protective factors	6906
EGF , bFGF , BDNF and NGF	6932
20	6956
50 ng/ml , IGF-I -- 50 ng/ml , LIF -- 0.5 u/ml , NAC -LRB- n-acetyl cystein -RRB- -- 10 µM , pifithrin a , cyclic -- 200 nM , and retinoic acid	6959
50 ng/ml , IGF-I	6959
50 ng/ml	6959
IGF-I	6969
50 ng/ml , LIF	6975
50 ng/ml	6975
LIF	6985
0.5 u/ml , NAC -LRB- n-acetyl cystein -RRB-	6989
0.5 u/ml	6989
NAC -LRB- n-acetyl cystein -RRB-	6999
NAC	6999
n-acetyl cystein	7004
10 µM , pifithrin a , cyclic	7023
10 µM , pifithrin a ,	7023
10 µM	7023
pifithrin a	7030
200 nM , and retinoic acid	7050
200 nM	7050
retinoic acid	7062
1	7076
5 µM	7078
The NVR-N-Gel	7084
polar and non-polar -LRB- hydrophobic -RRB- residues	7135
all	7179
cell cultivation	7220
the gel	7238
a concentration of 0.7 -- 1 % hyaluronic acid , however	7257
a concentration of 0.7	7257
a concentration	7257
0.7	7276
1 % hyaluronic acid , however	7280
1 %	7280
hyaluronic acid	7282
implantation	7312
a more viscous gel -LRB- 1.2 -- 1.5 % -RRB-	7325
a more viscous gel	7325
1.2 -- 1.5 %	7345
1.2	7345
1.5 %	7349
Cultivation of adult human NOM and embryonic spinal cord cells Biopsies of adult human olfactory nasal mucosa and embryonic spinal cords of aborted fetuses -LRB- 16 -- 23 weeks of gestation -RRB-	7364
Cultivation of adult human NOM and embryonic spinal cord cells Biopsies of adult human olfactory nasal mucosa and embryonic spinal cords of aborted fetuses	7364
Cultivation	7364
adult human NOM and embryonic spinal cord cells Biopsies of adult human olfactory nasal mucosa and embryonic spinal cords of aborted fetuses	7379
adult human NOM and embryonic spinal cord cells Biopsies of adult human olfactory nasal mucosa	7379
adult human NOM and embryonic spinal cord cells Biopsies	7379
adult human olfactory nasal mucosa	7439
embryonic spinal cords of aborted fetuses	7478
embryonic spinal cords	7478
aborted fetuses	7504
16	7521
23 weeks of gestation	7524
23 weeks	7524
gestation	7536
cell isolation and the establishment of cultures	7566
cell isolation	7566
the establishment of cultures	7585
the establishment	7585
cultures	7606
The study with human derived samples	7616
The study	7616
human derived samples	7631
the Helsinki committee of Assaf-Harofeh Medical Center -LRB- no. 13/03 -RRB-	7669
the Helsinki committee	7669
Assaf-Harofeh Medical Center -LRB- no. 13/03 -RRB-	7695
Assaf-Harofeh Medical Center	7695
no. 13/03	7725
Informed consent	7737
each patient	7772
An innovative culture technique	7786
the scheme -LRB- Fig. 2 -RRB-	7848
the scheme	7848
Fig. 2	7860
It	7869
stationary cultures in gel	7881
stationary cultures	7881
gel	7904
cells grown in suspension on an anion exchange , positively charged cylindrical , DEAE-cellulose -LRB- DE-53 -RRB- microcarriers -LRB- MCs -RRB- -LRB- Whatman , England -RRB-	7926
cells	7926
suspension	7941
an anion exchange , positively charged cylindrical , DEAE-cellulose -LRB- DE-53 -RRB- microcarriers -LRB- MCs -RRB- -LRB- Whatman , England -RRB-	7955
an anion exchange	7955
cylindrical , DEAE-cellulose -LRB- DE-53 -RRB- microcarriers -LRB- MCs -RRB- -LRB- Whatman , England -RRB-	7993
cylindrical , DEAE-cellulose -LRB- DE-53 -RRB- microcarriers -LRB- MCs -RRB-	7993
cylindrical , DEAE-cellulose -LRB- DE-53 -RRB- microcarriers	7993
cylindrical , DEAE-cellulose -LRB- DE-53 -RRB-	7993
microcarriers	8029
MCs	8044
Whatman	8050
England	8059
The MCs	8069
phosphate buffered saline -LRB- PBS -RRB- pH 7.4	8099
phosphate buffered saline -LRB- PBS -RRB-	8099
phosphate buffered saline	8099
PBS	8126
batches of 15 g in 100 ml PBS	8156
batches	8156
15 g in 100 ml PBS	8167
15 g	8167
100 ml PBS	8175
-LSB- 19 , 51 -RSB-	8186
The dissociated cells	8196
The	8196
cells	8212
suspension attached to the MCs for periods of 1 -- 4 weeks	8232
suspension	8232
the MCs for periods of 1 -- 4 weeks	8255
the MCs	8255
periods of 1 -- 4 weeks	8267
periods of 1	8267
periods	8267
1	8278
4 weeks	8280
various times during their growth period in suspension	8292
various times	8292
their growth period in suspension	8313
their growth period	8313
suspension	8336
cell-MC aggregates	8348
NVR-N-Gel as stationary cultures	8398
NVR-N-Gel	8398
stationary cultures	8411
The following growth media	8432
modified NEP medium based on the Bottenstein and Sato -LSB- 6 -RSB- N2 medium or M-21 medium	8470
modified NEP medium	8470
the Bottenstein and Sato -LSB- 6 -RSB- N2 medium or M-21 medium	8499
the Bottenstein and Sato	8499
6 -RSB- N2 medium or M-21 medium	8525
The NEP medium	8554
DMEM-F12 -LRB- Invitrogen , UK -RRB- , N2 additives -LRB- progesterone , putresine , selenium , insulin and transferrin -RRB- plus complex B27 supplements -LRB- Invitrogen -RRB- and 1 % BSA	8578
DMEM-F12 -LRB- Invitrogen , UK -RRB- , N2 additives -LRB- progesterone , putresine , selenium , insulin and transferrin -RRB-	8578
DMEM-F12	8578
Invitrogen	8588
UK	8600
N2 additives -LRB- progesterone , putresine , selenium , insulin and transferrin -RRB-	8605
N2 additives	8605
progesterone , putresine , selenium , insulin and transferrin	8619
progesterone	8619
putresine , selenium , insulin and transferrin	8633
complex B27 supplements -LRB- Invitrogen -RRB- and 1 % BSA	8684
complex B27 supplements -LRB- Invitrogen -RRB-	8684
complex B27 supplements	8684
Invitrogen	8709
1 % BSA	8725
The M-21 medium	8733
NEP medium	8761
that B27	8780
100 µM	8804
nonessential amino acids , 30 ng/ml triiodothyronine	8811
nonessential amino acids	8811
30 ng/ml triiodothyronine	8837
1 mM sodium pyruvate	8868
Both media	8900
the same factors used to enrich the gel	8934
the same factors	8934
the gel	8966
cell expansion	8979
the media	8995
10 % fetal calf serum -LRB- FCS -RRB-	9024
10 % fetal calf serum	9024
FCS	9046
growth differentiation and implantation	9056
the serum	9096
the media	9123
Cells	9134
3	9166
4 weeks	9168
implantation	9185
Surgical and transplantation procedure The study	9199
Surgical	9199
transplantation procedure The study	9212
transplantation procedure	9212
The study	9238
the local ethical committee for experiments in laboratory animals	9266
the local ethical committee	9266
experiments in laboratory animals	9298
experiments	9298
laboratory animals	9313
Animal treatment and maintenance	9333
Animal treatment	9333
maintenance	9354
accordance with the '' Guide for the care and use of animals '' , Institute of laboratory animal resources commission on life sciences , National Research Council , National Academy Press , Washington , DC , 1966	9374
accordance	9374
the '' Guide for the care and use of animals '' , Institute of laboratory animal resources commission on life sciences , National Research Council , National Academy Press , Washington , DC , 1966	9390
the	9390
Guide for the care and use of animals '' , Institute of laboratory animal resources commission	9396
the care and use of animals '' , Institute of laboratory animal resources	9406
the care and use	9406
animals '' , Institute of laboratory animal resources	9426
animals	9426
Institute of laboratory animal resources	9437
Institute	9437
laboratory animal resources	9450
life sciences , National Research Council , National Academy Press , Washington , DC , 1966	9492
life sciences	9492
National Research Council	9507
National Academy Press	9534
Washington	9558
DC	9570
1966	9574
The DHEW publication no. 80 -LRB- NIH -RRB- Office of Science and Health reports DRR/NIH , Bethesda , MD 20205 , USA .	9580
The DHEW publication no.	9580
80 -LRB- NIH -RRB-	9605
80	9605
NIH	9609
Office of Science and Health reports	9614
Office	9614
Science and Health reports	9624
DRR/NIH , Bethesda	9651
DRR/NIH	9651
Bethesda	9660
MD 20205	9670
USA	9680
Twenty Sprague-Dawly rats , 3-months old , each weighing approximately 250 g ,	9685
Twenty Sprague-Dawly rats	9685
each weighing approximately 250 g	9726
each	9726
approximately 250 g	9740
All rats	9772
intraperitoneal injections	9802
the operations	9834
anesthesia	9850
Ketamine HCL -LRB- 50501 USA -RRB- 125 -- 130 mg/kg and Xylosine -LRB- B2370 Belgium -RRB- 4.8 mg/kg	9874
Ketamine HCL -LRB- 50501 USA -RRB- 125	9874
Ketamine HCL	9874
50501 USA	9888
125	9899
130 mg/kg and Xylosine -LRB- B2370 Belgium -RRB- 4.8 mg/kg	9903
130 mg/kg	9903
Xylosine -LRB- B2370 Belgium -RRB- 4.8 mg/kg	9917
Xylosine	9917
B2370 Belgium	9927
4.8 mg/kg	9942
electrophysiological tests	9957
rats	9985
a short period -LRB- 30 min -RRB- with Ketamine 75 -- 85 mg/kg and Xylosine 3 mg/kg	10012
a short period -LRB- 30 min -RRB- with Ketamine 75	10012
a short period -LRB- 30 min -RRB-	10012
a short period	10012
30 min	10028
Ketamine 75	10041
85 mg/kg and Xylosine 3 mg/kg	10053
85 mg/kg	10053
Xylosine 3 mg/kg	10066
removal of stitches	10088
removal	10088
stitches	10099
light anesthesia	10109
50 mg/kg Ketamine and 1.8 mg/kg Xylosine	10136
50 mg/kg Ketamine	10136
1.8 mg/kg Xylosine	10158
All the treatments and the	10178
All the treatments	10178
the	10201
tests were performed in a double blind randomized manner	10215
tests	10215
a double blind randomized manner	10239
All surgical procedures	10273
anesthetized rats	10315
a high magnification navigator microscope -LRB- Zeiss NC-4 -RRB- in a class 100 animal operating room	10340
a high magnification navigator microscope -LRB- Zeiss NC-4 -RRB-	10340
a high magnification navigator microscope	10340
Zeiss NC-4	10383
a class 100 animal operating room	10398
a class	10398
100 animal operating room	10406
The spinal cord	10433
a dorsal approach	10465
The overlying muscles	10484
T7 -- T8 laminae	10522
T7	10522
T8 laminae	10525
the spinal cord	10545
micro-scissors	10593
a 4 mm segment of the cord	10612
a 4 mm segment	10612
the cord	10630
A 4 mm gap	10652
the gap size formed after removal of the scar in chronic spinal cord injuries	10683
the gap size	10683
removal of the scar in chronic spinal cord injuries	10709
removal	10709
the scar in chronic spinal cord injuries	10720
the scar	10720
chronic spinal cord injuries	10732
Eight of the 20 rats who underwent spinal cord transection and the removal of a 4 mm spinal cord segment	10762
Eight	10762
the 20 rats who underwent spinal cord transection and the removal of a 4 mm spinal cord segment	10771
the 20 rats	10771
spinal cord transection and the removal of a 4 mm spinal cord segment	10797
spinal cord transection	10797
the removal of a 4 mm spinal cord segment	10825
the removal of a 4 mm	10825
the removal	10825
a 4 mm	10840
spinal cord segment	10847
no further treatment -LRB- sham treated control group -RRB-	10885
no further treatment	10885
sham treated control group	10907
sham	10907
control group	10920
The remaining 12 rats	10936
implantation of one of the composite implants	10968
implantation	10968
one	10984
the composite implants	10991
Eight rats were treated with implants containing NOM cells -LRB- Fig. 3 -RRB- and four rats	11015
Eight rats	11015
implants containing NOM cells -LRB- Fig. 3 -RRB- and four rats	11044
implants	11044
NOM cells -LRB- Fig. 3 -RRB- and four rats	11064
NOM cells	11064
Fig. 3	11075
four rats	11087
human embryonal spinal cord-derived cells	11106
Embryonic human spinal cord cells	11149
as long term cultures	11194
the stage of myelin formation -LRB- Fig. 4 -RRB-	11219
the stage	11219
myelin formation -LRB- Fig. 4 -RRB-	11232
myelin formation	11232
Fig. 4	11250
1 -- 2 · 106 NOM or spinal cord cells	11265
1 -- 2 · 106 NOM	11265
1 -- 2	11265
· 106 NOM	11269
spinal cord cells	11282
NVR-N-Gel	11313
NVR scaffold	11344
the site of the excised spinal cord segment	11378
the site	11378
the excised spinal cord segment	11390
the	11390
spinal cord segment	11402
Four-millimeter long composite implants	11423
the transected area of the spinal cord , in direct contact	11478
the transected area	11478
the spinal cord	11501
direct contact	11521
the margins of the two stumps	11541
the margins	11541
the two stumps	11556
The entire area of the lesion containing the implant	11572
The entire area	11572
the lesion containing the implant	11591
the lesion	11591
the	11613
a thin biodegradable membrane composed of the biological copolymer , attached by a few interstitial sutures for fixation of the implants at the desired sites	11642
a thin biodegradable membrane	11642
the biological copolymer , attached by a few interstitial sutures for fixation of the implants at the desired sites	11684
the biological copolymer	11684
a few interstitial sutures	11722
fixation of the implants at the desired sites	11753
fixation	11753
the implants at the desired sites	11765
the implants	11765
the desired sites	11781
the muscular and cutaneous planes	11809
Post-operative animal maintenance	11868
the post-operative management of the animals care	11905
the post-operative management	11905
the animals care	11938
discomfort and pain	11977
implantation	12008
the rats	12021
urination and defecation	12047
the help of a veterinarian	12077
the help	12077
a veterinarian	12089
Animals	12118
ventilated cages , containing sterile sawdust and sterile food	12145
ventilated cages	12145
sterile sawdust and sterile food	12174
sterile sawdust	12174
sterile food	12194
The paraplegic rats	12208
solitary in cages	12238
solitary	12238
cages	12250
groups for 1 h every day	12278
groups	12278
1 h every day	12289
1 h	12289
every day	12293
a large facility	12307
the termination of the experiments	12328
the termination	12328
the experiments	12347
the animals	12364
general anesthesia	12398
Electrophysiological measurements Somatosensory evoked potentials -LRB- SSEP -RRB-	12418
Electrophysiological measurements	12418
Somatosensory	12452
potentials	12473
SSEP	12485
the experimental and control groups in a blinded manner	12508
the experimental and control groups	12508
a blinded manner	12547
3 months	12597
Conductivity of the spinal cord	12613
Conductivity	12613
the spinal cord	12629
stimulation of the sciatic nerve and recording from two disc-recording electrodes , active and reference , placed on the rats ' scalps	12660
stimulation	12660
the sciatic nerve and recording from two disc-recording electrodes	12675
the sciatic nerve and recording	12675
two disc-recording electrodes	12712
the rats ' scalps	12775
the rats '	12775
These electrodes , with conductive jelly ,	12793
These electrodes	12793
conductive jelly	12816
the scalp -- active over the somatosensory cortex in the midline and reference electrode between the two eyes	12851
the scalp	12851
the somatosensory cortex in the midline and reference electrode between the two eyes	12873
the somatosensory cortex	12873
the midline and reference electrode between the two eyes	12901
the midline and reference electrode	12901
the two eyes	12945
The earth electrode	12959
the thigh	12993
the side of the stimulation	13007
the side	13007
the stimulation	13019
The sciatic nerve	13036
a bipolar stimulating electrode	13072
Two hundred and fifty-six stimulation pulses of 0.1 ms in duration	13105
Two hundred and fifty-six stimulation pulses	13105
0.1 ms in duration	13153
0.1 ms	13153
duration	13163
a rate of 3 s -RRB-	13190
a rate	13190
3 s	13200
1	13204
The stimulus intensity	13207
slight twitching of the limb	13261
slight twitching	13261
the limb	13281
The appearance of evoked potentials , as a response to stimulation in two consecutive tests	13300
The appearance	13300
potentials	13325
a response to stimulation in two consecutive tests	13340
a response	13340
stimulation in two consecutive tests	13354
stimulation	13354
two consecutive tests	13369
Latency and amplitude -LRB- positive -- P wave peak -RRB-	13417
Latency and amplitude	13417
positive -- P wave peak	13440
positive	13440
P wave peak	13449
The rats	13476
diluted Nembutal	13526
15 mg/kg weight	13543
The test	13560
the Medelec/Teca Sapphire 4 ME electromyography apparatus -LRB- 20 Hz -- 2 KHz band pass filter and calibration sensitivity 10 -- 20 mcV/div and time base 5 ms/div -RRB-	13589
the Medelec/Teca Sapphire 4 ME electromyography apparatus	13589
20 Hz	13648
2 KHz band pass filter and calibration sensitivity 10 -- 20 mcV/div and time base 5 ms/div	13654
2 KHz band pass	13654
filter and calibration sensitivity 10 -- 20 mcV/div and time base 5 ms/div	13670
filter and calibration sensitivity 10	13670
filter and calibration sensitivity	13670
10	13705
20 mcV/div and time base 5 ms/div	13708
20 mcV/div	13708
time base 5 ms/div	13723
time base	13723
5 ms/div	13733
Locomotor rating scale The BBB scale -LSB- 5 -RSB-	13744
Locomotor rating scale	13744
The BBB scale	13767
5 -RSB-	13782
the locomotor rating scale , graded from 0 -LRB- absent performance -RRB- to 21 -LRB- complete normal gait performance -RRB-	13795
the locomotor rating scale	13795
0 -LRB- absent performance -RRB- to 21 -LRB- complete normal gait performance -RRB-	13835
0 -LRB- absent performance -RRB-	13835
0	13835
absent performance	13838
21 -LRB- complete normal gait performance -RRB-	13861
21	13861
complete normal gait performance	13865
This grading scale	13900
behavioral recovery and gait performance weekly for 2 -- 10 months after spinal cord injury	13938
behavioral recovery and gait performance weekly for 2	13938
behavioral recovery and gait performance weekly	13938
2	13990
10 months after spinal cord injury	13992
10 months	13992
spinal cord injury	14008
Magnetic resonance imaging -LRB- MRI -RRB- analysis Sample preparation : spinal cords were excised and fixed with formalin .	14028
Magnetic resonance imaging -LRB- MRI -RRB- analysis Sample preparation	14028
Magnetic resonance imaging	14028
MRI	14056
analysis Sample preparation	14061
spinal cords were excised and fixed with formalin	14090
spinal cords	14090
formalin	14131
The spinal cords	14141
5 mm NMRtubes with their long axis parallel	14177
5 mm NMRtubes	14177
their long axis parallel	14196
the z-direction -LRB- the Bo direction -RRB- of the magnet	14224
the z-direction -LRB- the Bo direction -RRB-	14224
the z-direction	14224
the Bo direction	14241
the magnet	14262
Fluorinert -LRB- Sigma Chemical Co. , St. Louis , MO , USA -RRB-	14289
Fluorinert	14289
Sigma Chemical Co.	14301
St. Louis	14321
MO , USA	14332
The temperature in the magnet	14342
The temperature	14342
the magnet	14361
25.0 ±	14390
0.1 C for the duration of the experiments	14395
0.1 C	14395
the duration of the experiments	14405
the duration	14405
the experiments	14421
The MRI diffusion experiments	14438
a wide-bore 8.4 T NMR spectrometer -LRB- Bruker , Karlsruhe , Germany -RRB- equipped with a micro5 imaging gradient probe capable of producing pulse gradients of up to 190 G cm -RRB- 1 in each of the three directions	14486
a wide-bore 8.4 T NMR spectrometer	14486
Bruker	14521
Karlsruhe	14529
Germany	14540
a micro5 imaging gradient probe capable of producing pulse gradients	14563
a micro5 imaging gradient probe	14563
pulse gradients	14616
up to 190 G cm	14635
190	14641
1	14650
each of the three directions	14655
each	14655
the three directions	14663
Diffusion	14685
MR images	14704
the stimulated	14735
diffusion imaging pulse sequence with the following parameters : TR = 2000 ms , TE = 35 ms , d = 3 ms , and D = 50 ms.	14755
diffusion imaging pulse sequence with the following parameters	14755
diffusion imaging pulse sequence	14755
the following parameters	14793
TR = 2000 ms , TE = 35 ms	14819
TR	14819
= 2000 ms , TE = 35 ms	14821
2000 ms , TE	14822
2000 ms	14822
TE	14831
d = 3 ms	14841
d	14841
= 3 ms	14842
3	14843
D = 50 ms.	14853
D	14853
= 50 ms.	14855
50	14856
The diffusion gradient strength , G ,	14863
The diffusion gradient strength	14863
G	14896
0	14920
60 G cm	14925
1 in 16 steps giving a maximal b value of 1.12 · 106 s cm -RRB- 2 and qmax of 766 cm -RRB- 1	14933
1	14933
16 steps giving a maximal b value of 1.12 · 106 s cm -RRB- 2 and qmax of 766 cm -RRB- 1	14938
16 steps	14938
a maximal b value of 1.12 · 106 s cm -RRB- 2 and qmax of 766 cm -RRB-	14954
a maximal b value	14954
1.12 · 106 s cm	14975
1.12 ·	14975
106 s cm	14980
106 s	14980
cm	14986
2 and qmax	14989
2	14989
qmax	14995
766 cm	15003
1	15010
Diffusion	15013
the long axis of the spine	15066
the long axis	15066
the spine	15083
The MR images	15094
a blind mode	15126
the trauma site	15143
the center of the imaged region	15173
the center	15173
the imaged region	15187
the	15187
region	15198
The signal decay of water	15206
The signal decay	15206
water	15226
the qspace approach -LSB- 12	15251
the qspace approach	15251
12	15272
the Matlab program	15282
Histological analyses	15302
cultivation , a small segment of the NOM biopsy	15333
cultivation	15333
a small segment of the NOM biopsy	15346
a small segment	15346
the NOM biopsy	15365
histological staining	15394
fixation in 10 % formalin	15422
fixation	15422
10 % formalin	15434
pH 7.4	15450
The spinal cord area	15458
the	15491
region	15503
both the proximal and the distal normal healthy stumps	15515
the proximal	15520
the distal normal healthy stumps	15537
a whole	15584
10 % formalin for several days	15601
10 % formalin	15601
several days	15618
samples	15646
ethylenediaminetetra-acetic acid -LRB- 12.5 % -RRB-	15669
ethylenediaminetetra-acetic acid	15669
12.5 %	15703
pH 7.0 for decalcification	15713
pH 7.0	15713
decalcification	15724
The softening of the calcified bony spine	15741
The softening	15741
the calcified bony spine	15758
the	15758
bony spine	15772
the smooth release of the whole region of the spinal cord , which could be inserted into the tube probe of the MRI system -LRB- described previously -RRB-	15791
the smooth release	15791
the whole region of the spinal cord , which could be inserted into the tube probe of the MRI system -LRB- described previously -RRB-	15813
the whole region	15813
the spinal cord , which could be inserted into the tube probe of the MRI system -LRB- described previously -RRB-	15833
the spinal cord	15833
the tube probe of the MRI system -LRB- described previously -RRB-	15879
the tube probe	15879
the MRI system	15897
histological analysis	15940
the spinal cord	15963
seven sections of 3 -- 4 mm each , in parallel	15998
seven sections of 3	15998
seven sections	15998
3	16016
4 mm each	16018
4 mm	16018
each	16023
parallel	16032
the MRI analysis	16046
The pieces	16064
tap water	16109
The samples	16120
sequential alcohols , xylol and embedded	16151
sequential alcohols	16151
xylol	16172
embedded	16182
paraffin	16194
Sections of 5 -- 6 µm were re-hydrated and stained with Meyer 's hematoxylin-eosin , Masson 's trichrome , and Bodian silver methods -LSB- 42 -RSB- .	16204
Sections of 5	16204
Sections	16204
5	16216
6 µm were re-hydrated and stained with Meyer 's hematoxylin-eosin , Masson 's trichrome , and Bodian silver methods -LSB- 42 -RSB-	16218
6 µm were re-hydrated and stained with Meyer 's hematoxylin-eosin	16218
6 µm	16218
Meyer 's hematoxylin-eosin	16257
Meyer 's	16257
Masson 's trichrome	16284
Masson 's	16284
Bodian silver methods -LSB- 42 -RSB-	16308
Bodian silver methods	16308
42 -RSB-	16331
Immunofluorescence Cultures	16336
4 % paraformaldehyde	16380
antibodies against epitopes of Olfactory Marker Protein -LRB- OMP was kindly provided by Prof. F. Margolis , University of Maryland , Baltimore , MD , USA -RRB- and microtubulin associated protein-2 -LRB- MAP-2 -RRB-	16419
antibodies against epitopes of Olfactory Marker Protein	16419
antibodies	16419
epitopes of Olfactory Marker Protein	16438
epitopes	16438
Olfactory Marker Protein	16450
OMP	16476
Prof. F. Margolis , University of Maryland , Baltimore , MD , USA	16503
Prof. F. Margolis	16503
University of Maryland , Baltimore , MD , USA	16522
University of Maryland , Baltimore , MD ,	16522
University	16522
Maryland , Baltimore , MD ,	16536
USA	16561
microtubulin associated protein-2 -LRB- MAP-2 -RRB-	16570
microtubulin associated protein-2	16570
MAP-2	16605
Cells	16613
CY2	16655
Texas Red	16662
goat anti-mouse or rabbit IgG -LRB- Jackson , diluted 1:100 -RRB-	16683
goat anti-mouse	16683
rabbit IgG -LRB- Jackson , diluted 1:100 -RRB-	16702
rabbit IgG	16702
Jackson , diluted 1:100	16714
Jackson	16714
1:100	16731
The stained cultures	16739
The	16739
cultures	16751
fluorescent microscope -LRB- Olympus , NY , USA -RRB-	16781
fluorescent microscope	16781
Olympus	16805
NY	16814
USA	16818
suitable filters	16828
Magnafire SP digital camera -LRB- Optronix , Mansfield NG , UK -RRB-	16868
Magnafire SP digital camera	16868
Optronix	16897
Mansfield NG	16907
UK	16921
positive control	16930
rat neuronal cultures	16948
the same conditions	16989
Results Table 1 BBB locomotor rating scale of the three groups of animals , two experimental and one control Fig. 1 A tubular scaffold containing nanofibers .	17011
Results	17011
Table 1 BBB locomotor rating scale of the three groups of animals , two experimental and one control Fig. 1	17019
Table 1 BBB locomotor rating scale	17019
Table 1	17019
BBB locomotor rating scale	17027
the three groups of animals , two	17057
the three groups	17057
animals , two	17077
animals	17077
two	17086
one control Fig. 1	17107
one control Fig.	17107
1	17125
A tubular scaffold containing nanofibers	17127
A tubular scaffold	17127
nanofibers	17157
Original magnification	17169
25 times	17192
Fig. 2 Preparation of adult human NOM and human embryonic SC cultures	17202
Fig. 2 Preparation	17202
adult human NOM and human embryonic SC cultures	17224
adult human NOM	17224
human embryonic SC cultures	17244
3 Cultured adult human NOM neurons	17278
3	17278
adult human NOM neurons	17289
a -- d Sprouting of nerve fibers concomitantly with migration of nerve cells from M-cell aggregates in NVR-N-Gel .	17314
a	17314
d Sprouting of nerve fibers concomitantly with migration of nerve cells from M-cell aggregates in NVR-N-Gel	17316
d Sprouting	17316
nerve fibers concomitantly with migration of nerve cells from M-cell aggregates in NVR-N-Gel	17331
nerve fibers	17331
migration of nerve cells from M-cell aggregates in NVR-N-Gel	17363
migration	17363
nerve cells from M-cell aggregates in NVR-N-Gel	17376
nerve cells	17376
M-cell aggregates in NVR-N-Gel	17393
M-cell aggregates	17393
NVR-N-Gel	17414
a -- c -- 200 times , d -- 100 times .	17425
a	17425
c -- 200 times , d -- 100 times	17427
c -- 200 times , d --	17427
c	17427
200 times , d	17429
200 times	17429
d	17440
100 times	17442
a -- d Phase contrast microscopy .	17453
a	17453
d Phase contrast microscopy	17455
Immunofluorescent staining of NOM neurons with antibodies specific to MAP 2 -LRB- e -RRB- and olfactory mucosa protein -LRB- OMP -RRB- -LRB- f -RRB- .	17484
Immunofluorescent staining	17484
NOM neurons	17514
antibodies specific to MAP 2 -LRB- e -RRB- and olfactory mucosa protein -LRB- OMP -RRB- -LRB- f -RRB-	17531
antibodies specific to MAP 2 -LRB- e -RRB- and olfactory mucosa protein -LRB- OMP -RRB-	17531
antibodies	17531
MAP 2 -LRB- e -RRB- and olfactory mucosa protein -LRB- OMP -RRB-	17554
MAP 2	17554
e	17561
olfactory mucosa protein	17568
OMP	17594
f	17600
Original magnification e -- 400 times , f -- 200 times , respectively Fig. 4 Phase contrast microscopy of mature motor neuron in a and myelinated axons in b -LRB- arrows -RRB- in long-term cultures of human embryonic spinal cord cells .	17604
Original magnification	17604
400 times , f -- 200 times , respectively Fig. 4 Phase contrast microscopy of mature motor neuron in a and myelinated axons in b -LRB- arrows -RRB- in long-term cultures of human embryonic spinal cord cells	17629
400 times	17629
f -- 200 times , respectively Fig. 4 Phase contrast microscopy of mature motor neuron in a and myelinated axons in b -LRB- arrows -RRB- in long-term cultures of human embryonic spinal cord cells	17640
f	17640
200 times , respectively Fig. 4 Phase contrast microscopy of mature motor neuron in a and myelinated axons in b -LRB- arrows -RRB- in long-term cultures of human embryonic spinal cord cells	17642
200 times	17642
Fig. 4 Phase contrast microscopy of mature motor neuron	17667
Fig. 4	17667
Phase contrast microscopy of mature motor neuron	17674
Phase contrast microscopy	17674
mature motor neuron	17703
a and myelinated axons in b -LRB- arrows -RRB- in long-term cultures of human embryonic spinal cord cells	17726
axons in b -LRB- arrows -RRB-	17743
axons	17743
b -LRB- arrows -RRB-	17752
b	17752
arrows	17755
long-term cultures of human embryonic spinal cord	17766
long-term cultures	17766
human embryonic spinal cord	17788
Original magnification 400 times Fig. 5 a Complete paralysis of both legs	17823
Original magnification 400 times	17823
Fig. 5	17857
a Complete paralysis of both legs	17864
a Complete paralysis	17864
both legs	17888
a control rat that underwent complete transection of the spinal cord and removal of a 4 mm segment	17917
a control rat	17917
complete transection of the spinal cord and removal of a 4 mm segment	17946
complete transection	17946
the spinal cord and removal of a 4 mm segment	17970
the spinal cord and removal	17970
a 4 mm segment	18001
b Paraplegic rat showing restoration of partial gait performance -LRB- in the right leg -RRB- 3 weeks after implantation of a composite	18017
b Paraplegic rat	18017
restoration of partial gait performance -LRB- in the right leg -RRB- 3 weeks	18042
restoration	18042
partial gait performance -LRB- in the right leg -RRB- 3 weeks	18057
partial gait performance -LRB- in the right leg -RRB-	18057
partial gait performance	18057
the right leg	18086
3 weeks	18101
implantation of a composite	18115
implantation	18115
a composite	18131
adult human NOM cells into a 4 mm gap of transected spinal cord	18171
adult human NOM cells	18171
a 4 mm gap of transected spinal cord	18198
a 4 mm gap	18198
transected spinal cord	18212
Fig. 6	18236
a Absence of spinal cord conductivity -LRB- SSEP -RRB- in a paraplegic control rat	18243
a Absence	18243
spinal cord conductivity -LRB- SSEP -RRB- in a paraplegic control rat	18256
spinal cord conductivity -LRB- SSEP -RRB-	18256
spinal cord conductivity	18256
SSEP	18282
a paraplegic control rat	18291
complete transection of the spinal cord and removal of 4 mm segment	18322
complete transection	18322
the spinal cord and removal of 4 mm segment	18346
the spinal cord and removal	18346
4 mm segment	18377
b Restoration of spinal cord conductivity after complete transection and implantation of composite	18391
b Restoration	18391
spinal cord conductivity after complete transection and implantation of composite	18408
spinal cord conductivity	18408
complete transection and implantation	18439
composite	18480
NOM Fig. 7 q-Space displacement maps -LRB- x direction -RRB- sequential slices of MRI analyses	18509
NOM Fig. 7 q-Space displacement maps -LRB- x direction -RRB- sequential slices	18509
NOM Fig. 7 q-Space displacement maps -LRB- x direction -RRB-	18509
NOM Fig.	18509
7 q-Space displacement maps -LRB- x direction -RRB-	18519
7 q-Space displacement maps	18519
x direction	18548
MRI analyses	18582
8 Histological sections of implanted spinal cords	18601
8 Histological sections	18601
implanted spinal cords	18628
10 months -LRB- a -- c -RRB-	18651
10 months	18651
a -- c	18662
a	18662
c	18664
adult NOM implantation and 3 months -LRB- d -RRB-	18673
adult NOM implantation	18673
3 months -LRB- d -RRB-	18700
d	18710
implantation of human embryonic spinal cord cells	18719
implantation	18719
human embryonic spinal cord cells	18735
Hematoxylin - eosin -LRB- H&E -RRB- staining demonstrates dispersed neuronal perikarya -LRB- a , arrows -RRB- .	18770
Hematoxylin	18770
eosin -LRB- H&E -RRB- staining demonstrates dispersed neuronal perikarya -LRB- a , arrows -RRB-	18783
eosin	18783
H&E	18790
staining	18795
dispersed neuronal perikarya -LRB- a , arrows -RRB-	18817
dispersed neuronal perikarya	18817
a , arrows	18847
a	18847
arrows	18850
Silver staining	18859
nerve fibers -- either single -LRB- b , arrows -RRB- ,	18888
nerve fibers	18888
either single -LRB- b , arrows -RRB-	18901
b , arrows	18916
b	18916
arrows	18919
parallel bundles -LRB- d , arrows -RRB-	18944
parallel bundles	18944
d , arrows	18962
d	18962
arrows	18965
addition	18977
note areas of neurokeratin -LRB- c , arrows -RRB-	18987
note areas	18987
neurokeratin -LRB- c , arrows -RRB-	19001
neurokeratin	19001
c , arrows	19015
c	19015
arrows	19018
Original magnification 400 times When adult human NOM cells were seeded directly in NVR-N-Gel as primary stationary cultures , growth of morphologically different cell types	19027
Original magnification	19027
400 times	19050
adult human NOM cells	19066
NVR-N-Gel	19112
primary stationary cultures , growth of morphologically different cell types	19125
primary stationary cultures	19125
growth of morphologically different cell types	19154
growth	19154
morphologically different cell types	19164
epithelial cells	19215
large laminae and tapered cells	19245
large laminae	19245
tapered cells	19263
islands of confluent cells	19285
islands	19285
confluent cells	19296
rise	19320
large numbers of round , unattached floating cell masses	19328
large numbers	19328
round , unattached floating cell masses	19345
round	19345
unattached floating cell masses	19352
A large number of neuronal cells	19385
A large number	19385
neuronal cells	19403
the epithelial laminae and the tapered cells	19438
the epithelial laminae	19438
the tapered cells	19465
the cultures that were reseeded in NVR-N-Gel , following a growth period of 1 -- 2 weeks in suspension on positively charged MCs -LRB- Fig. 4 -RRB-	19486
the cultures	19486
NVR-N-Gel	19521
a growth period of 1	19542
a growth period	19542
1	19561
2 weeks in suspension on positively charged MCs	19563
2 weeks	19563
suspension on positively charged MCs	19574
suspension	19574
positively charged MCs	19588
Fig. 4	19612
Post-operative observation Seven animals out of eight in the control group	19621
Post-operative observation	19621
Seven animals	19648
eight in the control group	19669
eight	19669
the control group	19678
complete paraplegic characteristics	19706
physical examination	19745
their gait performance analysis -LRB- BBB = 0 : no observable hind limb movement -RRB-	19773
their gait performance analysis	19773
BBB	19806
= 0 : no observable hind limb movement	19809
= 0	19809
no observable hind limb movement	19813
One rat of the control group	19848
One rat	19848
the control group	19859
slight movement of the hip joints -LRB- BBB = 1 -RRB- -LRB- Table 1 -RRB-	19884
slight movement	19884
the hip joints -LRB- BBB = 1 -RRB- -LRB- Table 1 -RRB-	19903
the hip joints -LRB- BBB = 1 -RRB-	19903
the hip joints	19903
BBB = 1	19919
Table 1	19927
Three of the eight rats in the group treated by a composite	19937
Three	19937
the eight rats in the group treated by a composite	19946
the eight rats	19946
the group treated by a composite	19964
the group	19964
a composite	19985
human NOM	20025
varying degrees of active movements	20042
varying degrees	20042
active movements	20061
One of the three rats	20079
One	20079
the three rats	20086
BBB = 3 -LRB- extensive movement of hip and knee joints -RRB-	20108
BBB	20108
3	20112
extensive movement of hip and knee joints	20115
extensive movement	20115
hip and knee joints	20137
one rat	20159
BBB = 10 -LRB- occasional weight-supported plantar steps ; no FL -- HL coordination -RRB-	20174
BBB	20174
10	20178
occasional weight-supported plantar steps ; no FL -- HL coordination	20182
occasional weight-supported plantar steps	20182
no FL -- HL coordination	20225
no FL	20225
HL coordination	20231
one rat	20252
BBB	20267
= 13 -LRB- frequent consistent weight-supported plantar steps and FL -- HL coordination -RRB- -LRB- Table 1 -RRB-	20270
= 13 -LRB- frequent consistent weight-supported plantar steps and FL -- HL coordination -RRB-	20270
= 13	20270
frequent consistent weight-supported plantar steps and FL -- HL coordination	20275
frequent consistent weight-supported plantar steps	20275
FL -- HL coordination	20330
FL	20330
HL coordination	20333
Table 1	20351
All four rats in the group treated by human embryonic spinal cord cells implantation	20361
All four rats	20361
the group treated by human embryonic spinal cord cells implantation	20378
the group	20378
human embryonic spinal cord cells implantation	20399
varying degrees of leg movements	20453
varying degrees	20453
leg movements	20472
one rat	20487
BBB = 3 -LRB- extensive movement of hip and knee joints -RRB-	20502
BBB	20502
3	20506
extensive movement of hip and knee joints	20509
extensive movement	20509
hip and knee joints	20531
one rat	20553
BBB = 6 -LRB- extensive movement of two joints and slight movement of the third -RRB-	20568
BBB	20568
6	20572
extensive movement of two joints and slight movement of the third	20575
extensive movement of two joints	20575
extensive movement	20575
two joints	20597
slight movement of the third	20612
slight movement	20612
the third	20631
one rat	20643
BBB = 10 -LRB- occasional weight-supported plantar steps ; no FL -- HL coordination -RRB-	20658
BBB	20658
10	20662
occasional weight-supported plantar steps ; no FL -- HL coordination	20666
occasional weight-supported plantar steps	20666
no FL -- HL coordination	20709
no FL	20709
HL coordination	20715
one rat	20737
BBB = 13 -LRB- frequent consistent weight-supported plantar steps and FL -- HL coordination -RRB-	20752
BBB	20752
13	20756
frequent consistent weight-supported plantar steps and FL -- HL coordination	20760
frequent consistent weight-supported plantar steps and FL -- HL	20760
frequent consistent weight-supported plantar steps	20760
FL -- HL	20815
FL	20815
HL	20818
coordination	20821
Table 1 , Fig. 5	20840
Table 1	20840
Fig. 5	20849
Statistical analyses of the three groups of animals	20858
Statistical analyses	20858
the three groups of animals	20882
the three groups	20882
animals	20902
the BBB scale	20920
The BBB scale	20934
a normal distribution -LRB- Shapiro-Wilk highly significant for two out of three groups -RRB-	20964
a normal distribution	20964
Shapiro-Wilk highly significant for two out of three groups	20987
Shapiro-Wilk highly significant for two out	20987
Shapiro-Wilk	20987
two	21023
three groups	21034
A non-parametric test	21049
the groups	21100
The Kruskal -- Wallis test shows a significant difference between the groups -LRB- p = 0.0117 -RRB- .	21112
The Kruskal	21112
Wallis test	21124
a significant difference between the groups -LRB- p = 0.0117 -RRB-	21142
a significant difference	21142
the groups -LRB- p = 0.0117 -RRB-	21175
the groups	21175
p	21187
0.0117	21189
the group pairs	21215
we	21259
the Duncan multiple comparison test on the ranked data -LRB- as the raw data is non-normal -RRB-	21267
the Duncan multiple comparison test	21267
the ranked data -LRB- as the raw data is non-normal -RRB-	21306
the ranked data	21306
the raw data	21326
The mean rank of human embryonic spinal cord group -LRB- 16.88 -RRB-	21355
The mean rank of human embryonic spinal cord group	21355
The mean rank	21355
human embryonic spinal cord group	21372
16.88	21407
both the human NOM and control groups	21443
the human NOM	21448
control groups	21466
means of 10.5 and 7.31 , respectively	21482
means of 10.5 and 7.31	21482
means	21482
10.5 and 7.31	21491
No significant difference	21521
the NOM and control groups	21570
the NOM	21570
control groups	21582
Electrophysiological measurements Spinal cord conductivities were measured immediately after spinal cord transection and again 3 months later in two groups -- transection alone , or transection plus implantation of composite NOMimplants .	21598
Electrophysiological measurements Spinal cord conductivities were measured immediately after spinal cord transection and again 3 months later in two groups	21598
Electrophysiological measurements	21598
Spinal cord conductivities	21632
spinal cord transection	21691
3 months	21725
two groups	21743
transection alone , or transection plus implantation of composite NOMimplants	21754
transection alone , or transection	21754
transection alone	21754
transection	21776
implantation of composite NOMimplants	21793
implantation	21793
composite NOMimplants	21809
two out of the three NOM implanted-rats exhibiting legs movements	21835
two	21835
the three NOM implanted-rats	21846
legs movements	21886
SSEPs	21902
Fig. 6b	21923
No SSEP response	21933
the eight rats of the control group	21966
the eight rats	21966
the control group	21984
the five rats of the NOM	22010
the five rats	22010
the NOM	22027
group that did not show leg movement -LRB- Fig. 6a -RRB-	22045
group	22045
leg movement -LRB- Fig. 6a -RRB-	22069
leg movement	22069
Fig. 6a	22083
MRI analysis Representatives of the treatment groups	22093
MRI analysis Representatives	22093
the treatment groups	22125
MRI analysis , which provided information on the state of the spinal cord tissue at the injury site	22164
MRI analysis	22164
information	22193
the state of the spinal cord tissue	22208
the state	22208
the spinal cord tissue	22221
the injury site	22247
Magnetic resonance -LRB- MR -RRB- q-space displacement	22264
Magnetic resonance -LRB- MR -RRB-	22264
Magnetic resonance	22264
MR	22284
-LSB- 1 , 2 -RSB- , which were computed for three different spinal cords ,	22314
-LSB- 1 , 2 -RSB-	22314
three different spinal cords	22346
fiber-like tissue with an amount of water-restricted diffusion	22390
fiber-like tissue	22390
an amount of water-restricted diffusion	22413
an amount	22413
water-restricted diffusion	22426
the treated spinal cords	22473
the controls -LRB- Fig. 7 -RRB-	22509
the controls	22509
Fig. 7	22523
comparison of slices numbers 3 -- 5 , which are of the implantation sites ,	22542
comparison	22542
slices numbers 3 -- 5	22556
slices numbers	22556
3 -- 5	22571
the implantation sites	22589
small areas in which the mean displacement is less than 4 µm -LRB- value consistent with normal white matter -RRB-	22618
small areas	22618
the mean displacement	22639
less than 4 µm -LRB- value consistent with normal white matter -RRB-	22664
less than 4 µm	22664
value	22680
normal white matter	22702
Such areas	22724
slices of implanted rats	22755
slices	22755
implanted rats	22765
the controls -LRB- Fig. 7 -RRB-	22792
the controls	22792
Fig. 7	22806
Histological analysis The dominant histological picture of the reparative tissue in the area of the excised cord tissue was the presence of fibrotic scar tissue	22815
Histological analysis	22815
The dominant histological picture of the reparative tissue in the area of the excised cord tissue	22837
The dominant histological picture	22837
the reparative tissue in the area of the excised cord tissue	22874
the reparative tissue	22874
the area of the excised cord tissue	22899
the area	22899
the excised cord tissue	22911
the	22911
cord tissue	22923
the presence of fibrotic scar tissue	22939
the presence	22939
fibrotic scar tissue	22955
glial cells and fibroblasts	22989
the formation of new blood vessels	23032
the formation	23032
new blood vessels	23049
No inflammatory reaction	23068
the histology of rats implanted with human cells or in the control rats	23116
the histology	23116
rats implanted with human cells or in the control rats	23133
rats	23133
human cells	23153
the control rats	23171
rats implanted with either human NOM or with embryonic spinal cord	23192
rats	23192
human NOM	23219
embryonic spinal cord	23237
the H&E	23259
sections	23275
some areas of neurokeratin -LRB- shrunk axons surrounded by an empty space , residual of the myelin sheath that had been dissolved by the alcohol treatment -RRB-	23291
some areas	23291
neurokeratin -LRB- shrunk axons surrounded by an empty space , residual of the myelin sheath that had been dissolved by the alcohol treatment -RRB-	23305
neurokeratin	23305
axons	23326
an empty space , residual of the myelin sheath that had been dissolved by the alcohol treatment	23346
an empty space	23346
residual of the myelin sheath that had been dissolved by the alcohol treatment	23362
residual	23362
the myelin sheath	23374
the alcohol treatment	23419
one rat	23459
the right leg	23488
NOM implantation	23508
a number of large neuronal perikarya	23526
a number	23526
large neuronal perikarya	23538
the implanted area -LRB- Fig. 8a , c -RRB-	23580
the implanted area	23580
Fig. 8a , c	23600
Fig. 8a	23600
c	23609
silver stained sections of both composite implants	23616
silver	23616
sections of both composite implants	23631
sections	23631
both composite implants	23643
Discussion Regeneration and repair of complete transection injuries of the spinal cord	23668
Discussion Regeneration and repair	23668
complete transection injuries of the spinal cord	23706
complete transection injuries	23706
the spinal cord	23739
an unresolved clinical challenge	23764
Various experimental approaches for reconstructive regeneration and renewal of damaged spinal cord	23798
Various experimental approaches	23798
reconstructive regeneration and renewal of damaged spinal cord	23834
reconstructive regeneration and renewal	23834
damaged spinal cord	23877
intensive investigation in laboratory animals	23907
intensive investigation	23907
laboratory animals	23934
The strategies	23954
stimulation of positive autoimmune responses -LSB- 16 , 50 -RSB- , introduction of neurotrophic and neuroprotective agents -LSB- 8 , 14 , 22 , 23 , 34 , 36 -RSB- , or removal and elimination of scar inhibitory molecules	23977
stimulation of positive autoimmune responses -LSB- 16	23977
stimulation	23977
positive autoimmune responses -LSB- 16	23992
positive autoimmune responses	23992
16	24023
50 -RSB- , introduction of neurotrophic and neuroprotective agents -LSB- 8 , 14 , 22 , 23 , 34 , 36 -RSB-	24027
50 -RSB-	24027
introduction of neurotrophic and neuroprotective agents -LSB- 8 , 14 , 22 , 23 , 34 , 36 -RSB-	24032
introduction of neurotrophic and neuroprotective agents	24032
introduction	24032
neurotrophic and neuroprotective agents	24048
-LSB- 8 , 14 , 22 , 23 , 34 , 36 -RSB-	24088
removal and elimination of scar inhibitory molecules	24116
removal and elimination	24116
scar inhibitory molecules	24143
-LSB- 11 , 21 , 24 , 30 , 53 -RSB-	24169
The latest technologies for solving paraplegic conditions	24191
The latest technologies	24191
paraplegic conditions	24227
several kinds of cell therapy that are introduced into the damaged site of the spinal cord after removal of the accumulated scar -LSB- 47 -RSB- : -LRB- a -RRB- Implantation of tissue-engineered devices , without cells , for anchorage of the implant and for guiding axonal regeneration -LSB- 59 , 60 -RSB-	24256
several kinds	24256
cell therapy	24273
the damaged site of the spinal cord	24311
the damaged site	24311
the spinal cord	24331
removal of the accumulated scar -LSB- 47 -RSB- : -LRB- a -RRB- Implantation of tissue-engineered devices	24353
removal	24353
the accumulated scar -LSB- 47 -RSB- : -LRB- a -RRB- Implantation of tissue-engineered devices	24364
the accumulated scar -LSB- 47 -RSB-	24364
the accumulated scar	24364
47 -RSB-	24386
-LRB- a -RRB- Implantation of tissue-engineered devices	24391
Implantation	24395
tissue-engineered devices	24411
cells , for anchorage of the implant and for guiding axonal regeneration -LSB- 59 , 60 -RSB-	24446
cells	24446
anchorage of the implant and for guiding axonal regeneration -LSB- 59 , 60 -RSB-	24457
anchorage	24457
the implant and for guiding axonal regeneration -LSB- 59 , 60 -RSB-	24470
guiding axonal regeneration -LSB- 59 , 60	24490
guiding axonal regeneration	24490
-LSB- 59 , 60	24518
Composite implants	24532
cells of either autologous or allogeneic origin -LSB- 18 , 35 , 37 , 41	24563
cells	24563
either autologous or allogeneic origin -LSB- 18 , 35 , 37 , 41	24572
either autologous or allogeneic origin	24572
-LSB- 18 , 35 , 37 , 41	24611
The choice of cell resources	24629
The choice	24629
cell resources	24643
stem cells directed to differentiate toward mature neurogenic phenotypes or insertion of already mature neuronal committed cells	24690
stem cells	24690
mature neurogenic phenotypes or insertion of already mature neuronal committed cells	24734
mature neurogenic phenotypes	24734
insertion of already mature neuronal committed cells	24766
insertion	24766
already mature neuronal committed cells	24779
the current project	24823
both cell sources of the composite implants	24844
both cell sources	24844
the composite implants	24865
human origin	24895
the rat spinal cord system	24920
xenogeneic cell implants	24950
they	24976
future clinical studies	24994
autologous -LRB- NOM cells -RRB- and allogeneic -LRB- embryonic spinal cord cells -RRB- sources , respectively	25030
autologous -LRB- NOM cells -RRB- and allogeneic -LRB- embryonic spinal cord cells -RRB- sources	25030
NOM cells	25042
embryonic spinal cord cells	25069
embryonic spinal cord	25069
cells	25091
The innovative cell culture techniques described in the Methods section	25121
The innovative cell culture techniques	25121
the Methods section	25173
the purpose of establishing high concentrations of neural cell cultures ideally -LSB- 19 , 51 -RSB-	25200
the purpose	25200
high concentrations of neural cell cultures ideally -LSB- 19 , 51 -RSB-	25228
high concentrations	25228
neural cell cultures ideally -LSB- 19 , 51 -RSB-	25251
neural cell cultures	25251
-LSB- 19 , 51 -RSB-	25280
These cells	25290
a milieu of a gel enriched with adhesive molecules -LSB- 13 , 38 -RSB- and neurotrophic and neuroprotective agents as antioxidants , which are released slowly	25318
a milieu of a gel enriched with adhesive molecules -LSB- 13 , 38	25318
a milieu	25318
a gel enriched with adhesive molecules -LSB- 13 , 38	25330
a gel	25330
adhesive molecules	25350
-LSB- 13 , 38	25369
neurotrophic and neuroprotective agents as antioxidants , which are released slowly	25382
neurotrophic and neuroprotective agents	25382
antioxidants , which are released slowly	25425
antioxidants	25425
addition	25469
the gel	25479
the nanofilaments in the tubular scaffold	25494
the nanofilaments	25494
the tubular scaffold	25515
The gel and the scaffold	25537
The gel	25537
the scaffold	25549
Other reports in the literature	25613
Other reports	25613
the literature	25630
auxiliary tissue - engineered products that promote neuronal and axonal growth , such as nanofibrils -LSB- 52 , 59 , 60 -RSB- , gels -LSB- 34 , 56 , 57 -RSB- and scaffolds -LSB- 22 , 54 , 55 -RSB-	25654
auxiliary tissue	25654
engineered products that promote neuronal and axonal growth , such as nanofibrils -LSB- 52 , 59 , 60 -RSB- , gels -LSB- 34 , 56 , 57 -RSB- and scaffolds -LSB- 22 , 54 , 55 -RSB-	25672
engineered products	25672
neuronal and axonal growth , such as nanofibrils -LSB- 52 , 59 , 60 -RSB- , gels -LSB- 34 , 56 , 57 -RSB- and scaffolds	25705
neuronal and axonal growth	25705
nanofibrils -LSB- 52 , 59 , 60 -RSB- , gels -LSB- 34 , 56 , 57 -RSB- and scaffolds	25741
nanofibrils	25741
52	25754
59	25758
60 -RSB-	25762
gels	25767
34	25773
56	25777
57 -RSB-	25781
scaffolds	25789
-LSB- 22 , 54 , 55 -RSB-	25799
Acellular devices yiel - ded poorer and limited results in comparison to cellcontaining implants -LSB- 47 -RSB- .	25813
Acellular devices	25813
poorer and limited results in comparison	25841
poorer and limited results	25841
comparison	25871
cellcontaining implants	25885
-LSB- 47	25909
A variety of sources for implantation	25915
A variety	25915
sources for implantation	25928
sources	25928
implantation	25940
bone marrow stroma cells -LSB- 25 , 33 , 58 -RSB- , skin , umbilical cord blood and embryonal and fetal stem cell lines -LSB- 20 , 37 , 41 , 43 , 61 -RSB-	25981
bone marrow stroma cells	25981
25 , 33 , 58 -RSB- , skin , umbilical cord blood and embryonal and fetal stem cell lines	26007
25	26007
33	26011
58 -RSB-	26015
skin	26020
umbilical cord blood	26026
embryonal and fetal stem cell lines	26051
-LSB- 20 , 37 , 41 , 43 , 61 -RSB-	26087
those cell sources	26118
only sporadic appearances of single cells or cell aggregates of neuronal cells	26160
only sporadic appearances	26160
single cells or cell aggregates of neuronal cells	26189
single cells or cell aggregates	26189
neuronal cells	26224
robust numbers of neuronal cells	26260
robust numbers	26260
neuronal cells	26278
a successful	26303
massive segmental losses	26341
the current study	26370
embryonic spinal cord and adult NOM cells	26389
vigorous vitality that established rich neurogenic cell cultures for implantation	26438
vigorous vitality	26438
rich neurogenic cell cultures	26473
implantation	26507
Both types of xenogeneic implants	26521
Both types	26521
xenogeneic implants	26535
the current study bear	26563
the risk of inducing an immunogenic response	26586
the risk	26586
an immunogenic response	26607
the results	26655
neither of them	26677
neither	26677
them	26688
a rejection response	26700
the other hand	26725
preliminary results of studies currently in progress	26741
preliminary results	26741
studies currently in progress	26764
studies	26764
progress	26785
NOM cells of adult dogs	26818
NOM cells	26818
adult dogs	26831
paralytic rats	26862
severe rejection	26878
the death of animals	26902
the death	26902
animals	26915
a few days	26923
the implantation	26940
It	26958
the spinal cord and its surrounding fluids	26987
the spinal cord	26987
its surrounding fluids	27007
an immunologically privileged site	27045
minimal immunologic responses	27086
The human embryonal spinal cord implants in our study	27117
The human embryonal spinal cord implants	27117
our study	27161
significant advantages	27178
the control animals	27206
repair of the tissue damage	27236
repair	27236
the tissue damage	27246
no means	27271
The rats implanted with the adult human NOM cells	27290
The rats	27290
the adult human NOM cells	27314
statistically insignificant advantages	27347
the control group of animals	27391
the control group	27391
animals	27412
the course of further experiments being performed	27424
the course	27424
further experiments being performed	27438
further experiments	27438
we	27475
more insight	27490
the growth of the human adult NOM biopsy	27508
the growth	27508
the human adult NOM biopsy	27522
further selecting	27553
specific sub-populations of cells	27590
specific sub-populations	27590
cells	27618
the overall collected mixture	27629
the overall	27629
mixture	27651
The outcome of these experiments	27660
The outcome	27660
these experiments	27675
the contribution of the different adult human NOM cell-populations	27713
the contribution	27713
the different adult human NOM cell-populations	27733
the recent years	27786
MRI	27803
the most important imaging modality for the central nervous system -LRB- CNS -RRB-	27826
the most important imaging modality	27826
the central nervous system -LRB- CNS -RRB-	27866
the central nervous system	27866
CNS	27894
Water diffusion	27900
an important contrast mechanism in MRI of the CNS	27919
an important contrast mechanism	27919
MRI of the CNS	27954
MRI	27954
the CNS	27961
diffusion weighted imaging -LRB- DWI -RRB- and diffusion tensor imagings -LRB- DTI -RRB-	27970
diffusion weighted imaging -LRB- DWI -RRB-	27970
diffusion weighted imaging	27970
DWI	27998
diffusion tensor imagings -LRB- DTI -RRB-	28007
diffusion tensor imagings	28007
DTI	28034
CNS pathologies and structures	28073
-LSB- 31 , 32 -RSB-	28104
The DTI	28114
fiber orientations	28154
31 -RSB-	28174
we	28189
high b-value q-space diffusion MRI	28215
the structural and the pathophysiological state of axons and fibers of the CNS -LSB- 1 -- 3 , 10 -RSB- , and thus can be used to study CNS maturation and degeneration -LSB- 3 -RSB-	28276
the structural	28276
the pathophysiological state of axons and fibers of the CNS -LSB- 1 -- 3 , 10 -RSB- , and thus can be used to study CNS maturation and degeneration -LSB- 3 -RSB-	28295
the pathophysiological state	28295
axons and fibers of the CNS	28327
axons and fibers	28327
the CNS	28347
1 -- 3 , 10 -RSB- ,	28356
1 -- 3	28356
10 -RSB-	28361
CNS maturation and degeneration -LSB- 3 -RSB-	28396
CNS maturation and degeneration	28396
3 -RSB-	28429
the current study	28451
the first two rats transplanted with cell-containing composite implants	28469
the first two rats	28469
cell-containing composite implants	28506
some regeneration of motor function and axons , consistent with the electrophysiological measurements , MRI , and some histological evidence of formation of cells and axonal fibers	28548
some regeneration	28548
motor function and axons	28569
the electrophysiological measurements , MRI , and some histological evidence of formation of cells and axonal fibers	28611
the electrophysiological measurements	28611
MRI	28650
some histological evidence of formation of cells and axonal fibers	28659
some histological evidence	28659
formation of cells and axonal fibers	28689
formation	28689
cells and axonal fibers	28702
cells	28702
axonal fibers	28712
It	28727
more MRI experiments	28744
these preliminary results	28789
axonal connection	28826
the transplanted zone	28874
Such MRI experiments	28897
underway	28922
The MRI analyses	28932
both the electrophysiological tests and the histological findings	28966
the electrophysiological tests	28971
the histological findings	29006
neuronal cells	29035
axons	29063
sections of the composite implanted transplants , versus their absence in the sections of the control animals	29075
sections	29075
the composite implanted transplants , versus their absence in the sections of the control animals	29087
the composite	29087
transplants , versus their absence	29111
transplants	29111
their absence	29131
the sections of the control animals	29148
the sections	29148
the control animals	29164
summary	29188
the current study	29200
we	29218
the combined efforts of cell cultivation , differentiation and integration	29230
the combined efforts	29230
cell cultivation , differentiation and integration	29254
cell cultivation	29254
differentiation	29272
integration	29292
a tissue-engineered scaffold	29309
a composite	29342
spinal cord injury	29376
Reliable tests to evaluate the final outcomes of the spinal cord injured regions	29396
the final outcomes of the spinal cord injured regions	29423
the final outcomes	29423
the spinal cord injured regions	29445
the spinal cord	29445
regions	29469
results that brought us closer to the goal of treatment of damaged spinal cord	29485
results	29485
us	29506
the goal of treatment of damaged spinal cord	29519
the goal	29519
treatment of damaged spinal cord	29531
treatment	29531
damaged spinal cord	29544
we	29579
the problem of elimination of scar tissue , which still needs to be addressed	29595
the problem	29595
elimination of scar tissue , which still needs to be addressed	29610
elimination	29610
scar tissue , which still needs to be addressed	29625
scar tissue	29625
These results	29673
we	29708
still a long way	29716
complete motor function and full gait performance	29746
complete motor function	29746
full gait performance	29774
